Retatrutide beat Ozempic in a head-to-head trial, highlighting Lilly’s dominance in its core area.
The GLP-1 market could reach $190 billion by 2035, and Eli Lilly leads the industry.
A deep pipeline can power another decade of market-beating returns.
The past decade has been eventful for Eli Lilly (NYSE:LLY). The company made significant breakthroughs in diabetes and weight loss, which helped drive its market value to over $1 trillion, making it the first healthcare stock to achieve that milestone. Eli Lilly's biggest growth drivers are currently Mounjaro for diabetes and Zepbound for weight management, which share the same active ingredient, tirzepatide.
Over the next five years, the pharmaceutical leader could earn approval for important brand-new drugs that will help send its sales even higher. And one of the company's candidates, retatrutide, recently posted excellent results in yet another clinical trial. Let's discuss what all that means for Eli Lilly's long-term prospects.
Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
Image source: Getty Images.
According to some estimates, the GLP-1 market could be valued at $190 billion by 2035, up from just $79 billion in 2025. Several factors will help propel this area much higher, including the fact that GLP-1 medicines may expand their reach across various therapeutic areas. Tirzepatide is a good test case here.
Not only is it approved for diabetes and weight management, but it has also earned an indication for obstructive sleep apnea. Further, in recent months, it has shown strong results as a combination treatment -- along with the immunosuppressant Taltz -- for certain autoimmune conditions, including plaque psoriasis. That's a key reason tirzepatide could generate about $62 billion in revenue by 2030, according to some estimates.
Competition will intensify, but Eli Lilly's pipeline could help it fend off other pharmaceutical giants. Consider that retatrutide recently completed a Phase 3 clinical trial in which it was pitted against Ozempic, a diabetes medicine marketed by Lilly's biggest competitor, Novo Nordisk (NYSE:NVO).
Retatrutide posted much higher A1C reductions and weight loss than the highest approved Ozempic dose. This is a meaningful win that could help improve Eli Lilly's long-term competitive position against the only company that has so far posed a serious threat. And the best part: There are more attractive candidates in the pipeline. Consider Eli Lilly's eloralintide.
This medicine mimics the amylin hormone, and it has shown highly promising results as a combo treatment, along with tirzepatide, in patients with type 2 diabetes and obesity. That's another product that could help Eli Lilly expand the market. There is also Foundayo, which could be particularly important for the pharmaceutical leader's global plans.
Foundayo is an oral GLP-1 medicine indicated for weight loss, but it is targeting additional approvals across diabetes, sleep apnea, hypertension, and more. Foundayo is likely cheaper to manufacture at scale than injectable medicines, more convenient for many patients, and may allow Eli Lilly to reach many more patients in developing countries, which is one of its long-term goals.
Most people with diabetes live in these regions, making this a massive opportunity for the company.
Given Eli Lilly's strong lineup and pipeline, there is a good chance that in 10 years, it will remain one of the leaders in its core therapeutic areas. But can the stock beat broader equities over the long run? In my view, it can. Not only is the company making excellent clinical and commercial progress in its core area, but its work in oncology, immunology, and neuroscience should also gradually improve its financial results.
For instance, in oncology, the company's Jaypirca recorded $228 million in revenue in the third quarter, growing 59% year over year, and this medicine is undergoing several clinical trials that could lead to label expansions. It was only approved in 2023, so it has years of growth ahead. Kisunla, a medicine for Alzheimer's disease, is also posting excellent sales growth while targeting various label expansions. These are only the tip of the iceberg.
Eli Lilly has a deep pipeline beyond GLP-1 products that could support strong sales and earnings growth over the long term and allow the company to deliver above-average returns once again. The stock could be significantly up from current levels in a decade. It is worth investing in Eli Lilly right now.
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*
Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 16, 2026.
Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool has a disclosure policy.